When to start treatment? A systematic approach to the comparison of dynamic regimes using observational data

International Journal of Biostatistics

Volumn 6, Issue 2, 2010, Pages

  Cain, Lauren E ^a   Robins, James M ^a   Lanoy, Emilie ^b   Logan, Roger ^a   Costagliola, Dominique ^c   Hernán, Miguel A ^d  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b INSERM U943 ^*  (United States)

^c SORBONNE UNIVERSITÉ   (France)

^d HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

Author keywords

Antiretroviral therapy; Dynamic treatment regimes; HIV infection; Marginal structural models

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; CD4 LYMPHOCYTE COUNT; DRUG DOSE REGIMEN; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; OBSERVATIONAL STUDY; TREATMENT PLANNING; COMPUTER SIMULATION; DECISION MAKING; EPIDEMIOLOGY; HUMAN; METHODOLOGY; STATISTICAL MODEL; TIME;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COMPUTER SIMULATION; CONFOUNDING FACTORS (EPIDEMIOLOGY); DECISION MAKING; HIV INFECTIONS; HUMANS; MODELS, STATISTICAL; RESEARCH DESIGN; TIME FACTORS;

EID: 77952041698     PISSN: 15574679     EISSN: None     Source Type: Journal    
DOI: 10.2202/1557-4679.1212     Document Type: Article

References (28)

1. Ancelle-Park, R., Klein, J. P., Stroobant, A., et al. (1993). Expanded European AIDS case definition. The Lancet 341, 441. (Pubitemid 23048185)
2. Cameron, D. W., Heath-Chiozzi, M., Danner, S., et al. (1998). Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. The Lancet 351, 543-549.
3. CDC (1992). 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morbidity and Mortality Weekly Report 41, 1-19.
4. Cole, S. R., and Hernán, M. A. (2008). Constructing inverse probability weights for marginal structural models. American Journal of Epidemiology 168, 656-664.
5. Cole, S. R., Hernán, M. A., Robins, J. M., et al. (2003). Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. American Journal of Epidemiology 158, 687-694.
6. Cole, S. R., Li, R., Anastos, K., et al. (2004). Accounting for leadtime in cohort studies: evaluating when to initiate HIV therapies. Statistics in Medicine 23, 3351-3363. (Pubitemid 39462092)
7. Hammer, S. M., Squires, K. E., Hughes, M. D., et al. (1997). A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. The New England Journal of Medicine 337, 725-733.
8. Hernán, M. A., Brumback, B., and Robins, J. M. (2000). Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 11, 561-570. (Pubitemid 30660035)
9. Hernán, M. A., Brumback, B., and Robins, J. M. (2001). Marginal structural models to estimate the joint causal effect of non-randomized treatments. Journal of the American Statistical Association 96, 440-448. (Pubitemid 33283729)
10. Hernán, M. A., Brumback, B. A., and Robins, J. M. (2002). Estimating the causal effect of zidovudine on CD4 count with a marginal structural model for repeated measures. Statistics in Medicine 21, 1689-1709.
11. Hernán, M. A., Lanoy, E., Costagliola, D., and Robins, J. M. (2006). Comparison of dynamic treatment regimes via inverse probability weighting. Basic & Clinical Pharmacology & Toxicology 98, 237-242.
12. Hernán M. A., and Taubman S. L. (2008). Does obesity shorten life? The importance of well defined interventions to answer causal questions. International Journal of Obesity 32, S8-S14.
13. HIV-CAUSAL Collaboration (2010). The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS 24, 123-137.
14. Orellana, L., Rotnitzky, A., and Robins, J. M. (2010a). Dynamic regime marginal structural mean models for estimation of optimal dynamic treatment regimes, Part I: Main Content. The International Journal of Biostatistics 6, Article 7.
15. Orellana, L., Rotnitzky, A., and Robins, J. M. (2010b). Dynamic regime marginal structural mean models for estimation of optimal dynamic treatment regimes, Part II: Proofs and Additional Results. The International Journal of Biostatistics 6, Article 8.
16. Panel on Antiretroviral Guidelines for Adults and Adolescents (2008). Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents: Department of Health and Human Services.
17. Piketty, C., Selinger-Leneman, H., Grabar, S., et al. (2008). Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. AIDS 22, 1203-1211.
18. Recommandations du groupe d'experts sous la direction du Pr P Yeni (2008). Prise en charge des personnes infectées par le VIH: Flammarion Médecines-Sciences.
19. Robins, J. M. (1987). Addendum to "A new approach to causal inference in mortality studies with sustained exposure periods - Application to control of the healthy worker survivor effect." Computers & Mathematics with Applications 14, 923-945
20. (errata in Computers & Mathematics with Applications 18, 477).
21. Robins, J. M., and Rotnitzky, A. (1992). Recovery of information and adjustment for dependent censoring using surrogate markers. In AIDS Epidemiology: Methodological Issues, N. P. Jewell, K. Dietz, and V. T. Farewell (eds), 297-331 (includes errata sheet). Boston, MA: Birkhäuser.
22. Robins, J. M., and Greenland, S. (2000). Comment on "Causal Inference Without Counterfactuals" by A. P. Dawid. Journal of the American Statistical Association - Theory and Methods 95, 477-482.
23. Robins, J., and Hernán, M. (2008). Estimation of the causal effects of timevarying exposures. In Longitudinal Data Analysis, G. Fitzmaurice, M. Davidian, G. Verbeke, and G. Molenberghs (eds), 553-599. New York: Chapman and Hall/CRC Press.
24. Robins, J., Orellana, L., and Rotnitzky, A. (2008). Estimation and extrapolation of optimal treatment and testing strategies. Statistics in Medicine 27, 4678-4721.
25. Sterne, J. A., Hernán, M. A., Ledergerber, B., et al. (2005). Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. The Lancet 366, 378-384. (Pubitemid 41073955)
26. Taubman, S. L., Robins, J. M., Mittleman, M. A., and Hernán, M. A. (2008). Alternative approaches to estimating the effects of hypothetical interventions. In: JSM Proceedings, Health Policy Statistics Section. Alexandria, VA: American Statistical Association.
27. van der Laan, M. J., and Petersen, M. L. (2007). Causal effect models for realistic individualized treatment and intention to treat rules. The International Journal of Biostatistics 3, Article 3.
28. Vander Weele, T. J. (2009). Concerning the consistency assumption in causal inference. Epidemiology 20, 880-883.